Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

iTeos Therapeutics logo

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Key Stats

Today's Range
$10.15
$10.15
50-Day Range
$10.09
$10.23
52-Week Range
$4.80
$17.63
Volume
N/A
Average Volume
1.51 million shs
Market Capitalization
$448.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Hold

Company Overview

Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ITOS Stock News Headlines

Wall Street legend: “Sell this A.I. stock now”
Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.tc pixel
See More Headlines

ITOS Stock Analysis - Frequently Asked Questions

iTeos Therapeutics, Inc. (NASDAQ:ITOS) released its quarterly earnings results on Wednesday, August, 6th. The company reported ($1.51) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $0.39.

iTeos Therapeutics (ITOS) raised $151 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/06/2025
Today
10/06/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITOS
CIK
1808865
Fax
N/A
Employees
90
Year Founded
2011

Price Target and Rating

High Price Target
$46.00
Low Price Target
$8.00
Potential Upside/Downside
+52.7%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$134.41 million
Net Margins
N/A
Pretax Margin
-336.72%
Return on Equity
-33.26%
Return on Assets
-28.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.53
Quick Ratio
7.53

Sales & Book Value

Annual Sales
$35 million
Price / Sales
12.82
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.17 per share
Price / Book
0.91

Miscellaneous

Outstanding Shares
44,210,000
Free Float
37,928,000
Market Cap
$448.73 million
Optionable
Optionable
Beta
1.31

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ITOS) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners